PubMed Health⌕ Search

Biomedical subjects

F Boulahbal

Publications and source records attributed to F Boulahbal.

At least 19 recordsLinked to original sources
PubMed1990

[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].

250 patients suffering from pulmonary tuberculosis who were smear positive received a chemotherapy regime for 6 months combining Rifampicin and Isoniazid every day with a daily supplement of Pyrazinamide for the first 8 weeks. The three drugs given in the initial phase of treatment were administered either separately or in combined preparations according to the 2 controlled randomised groups. During the maintenance phase the drugs were given in a combined form in fixed proportions in the 2 groups. 6 months after the end of treatment the bacteriological results were similar in the 2 groups in the 144 cases which were analysed. Amongst 137 cases with bacilli which were initially sensitive to Isoniazid (68 cases with separate medicines at the beginning and 69 with combined drugs) there was no failure at 6 months, nor any relapse during the course of the first period of surveillance. Amongst 7 cases with bacilli which were originally resistant to Isoniazid (4 and 3 respectively), there were 2 failures at 6 months one in each group with acquired resistance to Rifampicin observed at the time of the failure. There was no difference in the therapeutic results observed whatever the presentation of drugs used during the initial phase of treatment.

Drug Combinations↗
PubMed1989

[A controlled survey comparing 2 short-term therapeutic regimes in lymph node tuberculosis].

To study the efficacy of short term chemotherapy in the treatment of peripheral glandular tuberculosis a controlled trial was carried out in Algiers in March 1982 comparing two therapeutic regimes. All the patients admitted to the study presented with glandular tuberculosis which was proved either histologically or bacteriologically. They were recruited in three clinics serving the Algerian population and were required to live in Algiers. The two anti-tuberculous regimes used consisted of an initial phase of four drugs: Rifampicin (R), Isoniazid (H), Streptomycin (S) and Pyrazinamide (Z) every day for two months. This initial phase was followed by R.H. every day for four months in regime A, making six months treatment in all and for seven months in regime B making nine months treatment in all. 141 patients were thus admitted to the study, of whom 117 could be used for analysis at the end of treatment. Of these 68 were female making up 58% of the total. 12 patients or 10% were under 15 years of age. After two years of review following the end of treatment there were nine therapeutic failures (7.7%) of whom five were in regime A and four were in regime B (no significant difference). Amongst the failures large volume nodes persisted in three patients and two patients presented with new nodes. The lymph nodes increased in volume at the end of treatment in two cases; and finally two patients presented again with fistulae at the end of treatment. There were eight unfavourable outcomes in nine patients under observation during treatment or at the end of chemotherapy. There was only one failure noted some time after the finish of treatment at the end of two years of follow up.

Adolescent↗
PubMed1989

[Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].

250 patients suffering from smear positive pulmonary tuberculosis who had never been treated before, received a six-month regimen combining isoniazid and rifampicin every day with a supplement of pyrazinamide for the first eight weeks of treatment. The three drugs given during the initial phase of therapy were administered in two different forms: either as separate tablets or in a form combining all three drugs in fixed proportions (each tablet contained 50 mg of isoniazid, 120 mg of rifampicin and 300 mg of pyrazinamide). The patients were randomised into two groups of 125 receiving one or other combination of medications with the dose adapted for their weight. An analysis of the results at the end of the second month of treatment was carried out on 240 cases who could be analysed for tolerance and acceptability and in 193 cases who were analysed for the efficacy of therapy as judged by negative cultures. The treatment results were excellent in both groups, as was patient acceptability. The level of side effects was significantly lower in the group receiving combined medication (p less than 0.02). Both groups gave a similar proportion of negative cultures at the end of two months. The combined medicaments studied are thus well tolerated and at least as effective as individual drugs. They may thus replace them.

Adolescent↗
PubMed1985

[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months].

Three anti-tuberculous regimens were compared in Algiers. The three regimens use Isoniazid and Rifampicin every day for six months; two of them used a third drug, Ethambutol or Pyrazinamide for the first three months. The results at 12 months after cessation of chemotherapy have already been reported. At 30 months (or 24 months after the end of treatment) the results were analysed for 513 cases: in 27 cases (5%) there was a relapse or therapy failed. Of 21 relapses 13 occurred in the first six months of follow up, four during the next six months, three during the third and one in the final six months. No further relapse was seen between the thirtieth and forty second months. All the cases of failure or relapse had received an additive chemotherapy. Two patients were on chemotherapy again for a relapse noted in under six months; the other 25 patients had a satisfactory outcome after receiving a regime of six to 12 months containing Rifampicin in 21 cases or a regime 12 months without Rifampicin in four cases. There was no statistically significant difference between the three therapeutic series for those cases with tubercle bacilli initially sensitive to the antituberculous drugs. On the other hand, for primary Isoniazid resistance a third drug is essential during the initial treatment. In the overall analysis pyrazinamide was as effective as Ethambutol in avoiding failure due to primary drug resistance and relapses up to 30 months.

Antitubercular Agents↗
PubMed1983

[Comparison of 3 6-month chemotherapy regimes in pulmonary tuberculosis in routine practice in Algiers. 18th-month results].

Three 6 month antituberculous regimes were compared during a controlled trial in Algiers. Isoniazid and Rifampicin were used every day for six months in all three regimes; a third drug was used as a supplement in two of the three regimes during the first three months (Ethambutol or Pyrazinamide). The aim of the study was to assess the role of the third drug and also the suitability of a self-administered regime in routine practice. The results were analysed at eighteen months, twelve months after the end of therapy. The third drug had no influence on outcome in patients with sensitive organisms. There was a 2.5% relapse rate with no significant difference between the groups. On the other hand the third drug was crucial for those patients initially resistant to Isoniazid, because a relapse or failure due to primary resistance was avoided. The 6 month regimes were well tolerated: the treatment was only changed in 0.8% of cases for major toxicity. Finally, short self-administered oral regimens were well tolerated by the patients.

Adolescent↗
PubMed1979

Evaluation of the chloride and bromide salts of cetylpyridium for the transportation of sputum in tuberculosis bacteriology.

The usefulness of cetylpyridium chloride and cetylpyridium bromide, at a final concentration of 1% in 1% solution of sodium chloride, for the transportation of sputum in tuberculosis bacteriology, was evaluated. It was found that these compounds did not alter the staining properties nor the viability of the tubercle bacilli for at least 14 days.

Bacteriological Techniques↗
PubMed1977

[Note on the quality control of microscopists].

The decentralisation of the microscopic diagnosis of pulmonary tuberculosis is a valid policy for large countries with developing economies. But one must be assured that the work of the microscopists is reliable and uniform. To this end, a technique for the control of microscopists was tested; it consisted of a second reading of the examined smears in the peripheral centers.

Clinical Laboratory Techniques↗
PubMed1977

[Bacteriological aspects of extrarespiratory tuberculosis].

775 strains of extrapulmonary tubercle bacilli isolated during four years (1968-1972) were studied. Our results enabled us to confirm the paucibacillary nature of these tuberculous sites and the variety of their resistance to antibiotics. The comparison between the levels and types of primary resistance in pulmonary and extrapulmonary tuberculosis enabled us to better understand the transmission mechanisms of the tubercle bacilli in the community and its progress in the infected organism.

Adolescent↗
PubMed1977

[Prospective survey on the organization and supervision of the bacteriological diagnosis of pulmonary tuberculosis in a screening system in Algeria].

A prospective investigation was conducted in the western region of Algiers in 1974 in order to compare the effectiveness of the different methods of bacteriological diagnosis, the operational efficiency of its centralisation or decentralisation, and to evaluate the various methods of supervision. The results obtained favored the decentralisation of the microscopy centers at the peripheral level with permanent supervision by a regional or central laboratory.

Algeria↗